Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines

Howard Strickler, James J. Goedert, Susan S. Devesa, John Lahey, Joseph F. Fraumeni, Philip S. Rosenberg

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: Poliovirus vaccines that were used during the late 1950s and early 1960s were contaminated with simian virus 40 (SV40), a monkey virus that is tumorigenic in rodents. SV40 DNA sequences have been detected in some human cancers, especially pleural mesotheliomas, although results are conflicting. We examined the relationship between SV40-contaminated poliovirus vaccine exposure and subsequent rates of pleural mesothelioma in the United States. Methods: We used data from the Surveillance, Epidemiology, and End Results Program to estimate age- and sex-specific pleural mesothelioma incidence rates per 105 person-years (py) from 1975 through 1997 and the Poisson distribution to determine 95% confidence intervals (CIs) for, each rate. The prevalence, by birth cohort, of poliovirus vaccine exposure during the period of widespread SV40 contamination was determined from published survey data. Trends in mesothelioma incidence rates were assessed by examining age- and sex-specific rates over calendar periods and with the use of the age-period-cohort model. Trends in mesothelioma incidence were then compared with trends in prevalence of exposure. All statistical tests were two-sided. Results: The age-standardized pleural mesothelioma incidence rate for 1975 through 1997 was 1.29/105 py (95% CI = 1.24/105 to 1.34/105 py) in males and 0.21/105 py (95% CI = 0.20/105 to 0.23/105 py) in females. The rate in males increased from 0.79/105 py (95% CI = 0.62/105 to 1.0/105 py) in 1975 to a peak of 1.69/105 py (95% CI = 1.46/105 to 1.95/105 py) in 1992. Incidence rates increased the most among males who were 75 years of age or older, the age group least likely to have been immunized against poliovirus. Incidence rates among males in the age groups most heavily exposed to SV40-contaminated poliovirus vaccine remained stable or decreased from 1975 through 1997. Similar age-specific trends were observed among females. The age-period-cohort models for men and women also indicated that the trends in pleural mesothelioma incidence were not related to trends in exposure to SV40-contaminated poliovirus vaccine. Conclusions: Age-specific trends in U.S. pleural mesothelioma incidence rates are not consistent with an effect of exposure to SV40-contaminated poliovirus vaccine. Nonetheless, given reports of the detection of SV40 genomic DNA sequences in human mesotheliomas, monitoring of vaccine-exposed cohorts should continue.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalJournal of the National Cancer Institute
Volume95
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Poliovirus Vaccines
Simian virus 40
Mesothelioma
Incidence
Confidence Intervals
Age Groups
SEER Program
Poisson Distribution
Poliovirus
Haplorhini
Rodentia
Vaccines
Parturition
Viruses

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. / Strickler, Howard; Goedert, James J.; Devesa, Susan S.; Lahey, John; Fraumeni, Joseph F.; Rosenberg, Philip S.

In: Journal of the National Cancer Institute, Vol. 95, No. 1, 01.01.2003, p. 38-45.

Research output: Contribution to journalArticle

Strickler, Howard ; Goedert, James J. ; Devesa, Susan S. ; Lahey, John ; Fraumeni, Joseph F. ; Rosenberg, Philip S. / Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. In: Journal of the National Cancer Institute. 2003 ; Vol. 95, No. 1. pp. 38-45.
@article{651d2a58bb134e658bacdc2798404a19,
title = "Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines",
abstract = "Background: Poliovirus vaccines that were used during the late 1950s and early 1960s were contaminated with simian virus 40 (SV40), a monkey virus that is tumorigenic in rodents. SV40 DNA sequences have been detected in some human cancers, especially pleural mesotheliomas, although results are conflicting. We examined the relationship between SV40-contaminated poliovirus vaccine exposure and subsequent rates of pleural mesothelioma in the United States. Methods: We used data from the Surveillance, Epidemiology, and End Results Program to estimate age- and sex-specific pleural mesothelioma incidence rates per 105 person-years (py) from 1975 through 1997 and the Poisson distribution to determine 95{\%} confidence intervals (CIs) for, each rate. The prevalence, by birth cohort, of poliovirus vaccine exposure during the period of widespread SV40 contamination was determined from published survey data. Trends in mesothelioma incidence rates were assessed by examining age- and sex-specific rates over calendar periods and with the use of the age-period-cohort model. Trends in mesothelioma incidence were then compared with trends in prevalence of exposure. All statistical tests were two-sided. Results: The age-standardized pleural mesothelioma incidence rate for 1975 through 1997 was 1.29/105 py (95{\%} CI = 1.24/105 to 1.34/105 py) in males and 0.21/105 py (95{\%} CI = 0.20/105 to 0.23/105 py) in females. The rate in males increased from 0.79/105 py (95{\%} CI = 0.62/105 to 1.0/105 py) in 1975 to a peak of 1.69/105 py (95{\%} CI = 1.46/105 to 1.95/105 py) in 1992. Incidence rates increased the most among males who were 75 years of age or older, the age group least likely to have been immunized against poliovirus. Incidence rates among males in the age groups most heavily exposed to SV40-contaminated poliovirus vaccine remained stable or decreased from 1975 through 1997. Similar age-specific trends were observed among females. The age-period-cohort models for men and women also indicated that the trends in pleural mesothelioma incidence were not related to trends in exposure to SV40-contaminated poliovirus vaccine. Conclusions: Age-specific trends in U.S. pleural mesothelioma incidence rates are not consistent with an effect of exposure to SV40-contaminated poliovirus vaccine. Nonetheless, given reports of the detection of SV40 genomic DNA sequences in human mesotheliomas, monitoring of vaccine-exposed cohorts should continue.",
author = "Howard Strickler and Goedert, {James J.} and Devesa, {Susan S.} and John Lahey and Fraumeni, {Joseph F.} and Rosenberg, {Philip S.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "95",
pages = "38--45",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines

AU - Strickler, Howard

AU - Goedert, James J.

AU - Devesa, Susan S.

AU - Lahey, John

AU - Fraumeni, Joseph F.

AU - Rosenberg, Philip S.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: Poliovirus vaccines that were used during the late 1950s and early 1960s were contaminated with simian virus 40 (SV40), a monkey virus that is tumorigenic in rodents. SV40 DNA sequences have been detected in some human cancers, especially pleural mesotheliomas, although results are conflicting. We examined the relationship between SV40-contaminated poliovirus vaccine exposure and subsequent rates of pleural mesothelioma in the United States. Methods: We used data from the Surveillance, Epidemiology, and End Results Program to estimate age- and sex-specific pleural mesothelioma incidence rates per 105 person-years (py) from 1975 through 1997 and the Poisson distribution to determine 95% confidence intervals (CIs) for, each rate. The prevalence, by birth cohort, of poliovirus vaccine exposure during the period of widespread SV40 contamination was determined from published survey data. Trends in mesothelioma incidence rates were assessed by examining age- and sex-specific rates over calendar periods and with the use of the age-period-cohort model. Trends in mesothelioma incidence were then compared with trends in prevalence of exposure. All statistical tests were two-sided. Results: The age-standardized pleural mesothelioma incidence rate for 1975 through 1997 was 1.29/105 py (95% CI = 1.24/105 to 1.34/105 py) in males and 0.21/105 py (95% CI = 0.20/105 to 0.23/105 py) in females. The rate in males increased from 0.79/105 py (95% CI = 0.62/105 to 1.0/105 py) in 1975 to a peak of 1.69/105 py (95% CI = 1.46/105 to 1.95/105 py) in 1992. Incidence rates increased the most among males who were 75 years of age or older, the age group least likely to have been immunized against poliovirus. Incidence rates among males in the age groups most heavily exposed to SV40-contaminated poliovirus vaccine remained stable or decreased from 1975 through 1997. Similar age-specific trends were observed among females. The age-period-cohort models for men and women also indicated that the trends in pleural mesothelioma incidence were not related to trends in exposure to SV40-contaminated poliovirus vaccine. Conclusions: Age-specific trends in U.S. pleural mesothelioma incidence rates are not consistent with an effect of exposure to SV40-contaminated poliovirus vaccine. Nonetheless, given reports of the detection of SV40 genomic DNA sequences in human mesotheliomas, monitoring of vaccine-exposed cohorts should continue.

AB - Background: Poliovirus vaccines that were used during the late 1950s and early 1960s were contaminated with simian virus 40 (SV40), a monkey virus that is tumorigenic in rodents. SV40 DNA sequences have been detected in some human cancers, especially pleural mesotheliomas, although results are conflicting. We examined the relationship between SV40-contaminated poliovirus vaccine exposure and subsequent rates of pleural mesothelioma in the United States. Methods: We used data from the Surveillance, Epidemiology, and End Results Program to estimate age- and sex-specific pleural mesothelioma incidence rates per 105 person-years (py) from 1975 through 1997 and the Poisson distribution to determine 95% confidence intervals (CIs) for, each rate. The prevalence, by birth cohort, of poliovirus vaccine exposure during the period of widespread SV40 contamination was determined from published survey data. Trends in mesothelioma incidence rates were assessed by examining age- and sex-specific rates over calendar periods and with the use of the age-period-cohort model. Trends in mesothelioma incidence were then compared with trends in prevalence of exposure. All statistical tests were two-sided. Results: The age-standardized pleural mesothelioma incidence rate for 1975 through 1997 was 1.29/105 py (95% CI = 1.24/105 to 1.34/105 py) in males and 0.21/105 py (95% CI = 0.20/105 to 0.23/105 py) in females. The rate in males increased from 0.79/105 py (95% CI = 0.62/105 to 1.0/105 py) in 1975 to a peak of 1.69/105 py (95% CI = 1.46/105 to 1.95/105 py) in 1992. Incidence rates increased the most among males who were 75 years of age or older, the age group least likely to have been immunized against poliovirus. Incidence rates among males in the age groups most heavily exposed to SV40-contaminated poliovirus vaccine remained stable or decreased from 1975 through 1997. Similar age-specific trends were observed among females. The age-period-cohort models for men and women also indicated that the trends in pleural mesothelioma incidence were not related to trends in exposure to SV40-contaminated poliovirus vaccine. Conclusions: Age-specific trends in U.S. pleural mesothelioma incidence rates are not consistent with an effect of exposure to SV40-contaminated poliovirus vaccine. Nonetheless, given reports of the detection of SV40 genomic DNA sequences in human mesotheliomas, monitoring of vaccine-exposed cohorts should continue.

UR - http://www.scopus.com/inward/record.url?scp=0037248705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037248705&partnerID=8YFLogxK

M3 - Article

C2 - 12509399

AN - SCOPUS:0037248705

VL - 95

SP - 38

EP - 45

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -